Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3.

Nguyen BO, Rienstra M, Hobbelt AH, Tijssen JGP, Smit MD, Tieleman RG, Geelhoed B, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC; RACE 3 Investigators.

Am Heart J. 2020 Jan 10. pii: S0002-8703(19)30345-X. doi: 10.1016/j.ahj.2019.12.005. [Epub ahead of print] No abstract available.

PMID:
32067695
2.

DLL3: an emerging target in small cell lung cancer.

Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K.

J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. Review.

3.

Flow Cytometry-Based Characterization of Mast Cells in Human Atherosclerosis.

Kritikou E, Depuydt MAC, de Vries MR, Mulder KE, Govaert AM, Smit MD, van Duijn J, Foks AC, Wezel A, Smeets HJ, Slütter B, Quax PHA, Kuiper J, Bot I.

Cells. 2019 Apr 9;8(4). pii: E334. doi: 10.3390/cells8040334.

4.

Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study.

De With RR, Rienstra M, Smit MD, Weijs B, Zwartkruis VW, Hobbelt AH, Alings M, Tijssen JGP, Brügemann J, Geelhoed B, Hillege HL, Tukkie R, Hemels ME, Tieleman RG, Ranchor AV, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC.

Europace. 2019 Apr 1;21(4):563-571. doi: 10.1093/europace/euy311.

PMID:
30629160
5.

Risk Factor Management in Atrial Fibrillation.

Brandes A, Smit MD, Nguyen BO, Rienstra M, Van Gelder IC.

Arrhythm Electrophysiol Rev. 2018 Jun;7(2):118-127. doi: 10.15420/aer.2018.18.2. Review.

6.

Integrated care to reduce atrial fibrillation burden: do not underrate the overweight!

Smit MD, Rienstra M, Tieleman RG, Van Gelder IC.

Europace. 2018 Dec 1;20(12):1875-1876. doi: 10.1093/europace/euy137. No abstract available.

PMID:
29912313
7.

Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.

Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brügemann J, Geelhoed B, Tieleman RG, Hillege HL, Tukkie R, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC; RACE 3 Investigators.

Eur Heart J. 2018 Aug 21;39(32):2987-2996. doi: 10.1093/eurheartj/ehx739.

PMID:
29401239
8.

Preoperative fasting times: Prescribed and actual fasting times at Universitas Hospital Annex, Bloemfontein, South Africa.

Lamacraft G, Labuschagne C, Pretorius S, Prinsloo MC, Smit MD, Steyn JR.

S Afr Med J. 2017 Sep 22;107(10):910-914. doi: 10.7196/SAMJ.2017.v107i10.10930.

9.

Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation.

Smit MD, Van Gelder IC.

Evid Based Med. 2017 Jun;22(3):107-108. doi: 10.1136/ebmed-2017-110694. Epub 2017 May 16. No abstract available.

PMID:
28512109
10.

Atrial fibrillation: a mechanism or just a bystander?

Smit MD, Van Gelder IC.

Europace. 2017 Sep 1;19(9):1413-1415. doi: 10.1093/europace/eux040. No abstract available.

PMID:
28407056
11.

Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study.

Alings M, Smit MD, Moes ML, Crijns HJ, Tijssen JG, Brügemann J, Hillege HL, Lane DA, Lip GY, Smeets JR, Tieleman RG, Tukkie R, Willems FF, Vermond RA, Van Veldhuisen DJ, Van Gelder IC.

Neth Heart J. 2013 Jul;21(7-8):354-63. doi: 10.1007/s12471-013-0428-5.

12.

Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.

Smit MD, Moes ML, Van Gelder IC.

Lancet. 2012 Oct 27;380(9852):1467; author reply 1468. doi: 10.1016/S0140-6736(12)61831-5. No abstract available.

PMID:
23101705
13.

The importance of whether atrial fibrillation or heart failure develops first.

Smit MD, Moes ML, Maass AH, Achekar ID, Van Geel PP, Hillege HL, van Veldhuisen DJ, Van Gelder IC.

Eur J Heart Fail. 2012 Sep;14(9):1030-40. doi: 10.1093/eurjhf/hfs097. Epub 2012 Jun 25.

14.

Role of inflammation in early atrial fibrillation recurrence.

Smit MD, Maass AH, De Jong AM, Muller Kobold AC, Van Veldhuisen DJ, Van Gelder IC.

Europace. 2012 Jun;14(6):810-7. doi: 10.1093/europace/eur402. Epub 2012 Jan 10.

PMID:
22237586
15.

Planning and monitoring of patients for electrical cardioversion for atrial fibrillation.

Deuling JH, Vermeulen RP, Smit MD, van der Maaten JM, Boersema HM, van den Heuvel AF, Van Gelder IC.

Neth Heart J. 2012 Apr;20(4):148-54. doi: 10.1007/s12471-011-0208-z.

16.

New treatment options for atrial fibrillation: towards patient tailored therapy.

Smit MD, Van Gelder IC.

Heart. 2011 Nov;97(21):1796-802. doi: 10.1136/heartjnl-2011-300276. Review. No abstract available.

PMID:
21984172
17.

Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study.

Smit MD, Crijns HJ, Tijssen JG, Hillege HL, Alings M, Tuininga YS, Groenveld HF, Van den Berg MP, Van Veldhuisen DJ, Van Gelder IC; RACE II Investigators.

J Am Coll Cardiol. 2011 Aug 23;58(9):942-9. doi: 10.1016/j.jacc.2011.04.030.

18.

Rationale and current perspective for early rhythm control therapy in atrial fibrillation.

Van Gelder IC, Haegeli LM, Brandes A, Heidbuchel H, Aliot E, Kautzner J, Szumowski L, Mont L, Morgan J, Willems S, Themistoclakis S, Gulizia M, Elvan A, Smit MD, Kirchhof P.

Europace. 2011 Nov;13(11):1517-25. doi: 10.1093/europace/eur192. Epub 2011 Jul 22. Review.

19.

Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap?

Smit MD, Van Gelder IC.

Neth Heart J. 2011 May;19(5):212-3. doi: 10.1007/s12471-011-0119-z. No abstract available.

20.

Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy.

Smit MD, Maass AH, Hillege HL, Wiesfeld AC, Van Veldhuisen DJ, Van Gelder IC.

Eur J Heart Fail. 2011 May;13(5):543-50. doi: 10.1093/eurjhf/hfr006. Epub 2011 Feb 17.

21.

Cardiac gene expression profiling - the quest for an atrium-specific biomarker.

Maass AH, De Jong AM, Smit MD, Gouweleeuw L, de Boer RA, Van Gilst WH, Van Gelder IC.

Neth Heart J. 2010 Dec;18(12):610-4.

23.

Guidelines for atrial fibrillation in heart failure need to be clarified.

Smit MD, Van Veldhuisen DJ, Van Gelder IC.

J Am Coll Cardiol. 2010 Jan 12;55(2):167; author reply 168-9. doi: 10.1016/j.jacc.2009.05.081. No abstract available.

24.

Myocardial perfusion imaging does not adequately assess the risk of coronary artery disease in patients with atrial fibrillation.

Smit MD, Tio RA, Slart RH, Zijlstra F, Van Gelder IC.

Europace. 2010 May;12(5):643-8. doi: 10.1093/europace/eup404. Epub 2009 Dec 17.

PMID:
20022875
25.

Valsartan and recurrent atrial fibrillation.

Smit MD, Van Gelder IC.

N Engl J Med. 2009 Jul 30;361(5):532; author reply 533. doi: 10.1056/NEJMc091057. No abstract available.

PMID:
19641214
26.

Upstream therapy of atrial fibrillation.

Smit MD, Van Gelder IC.

Expert Rev Cardiovasc Ther. 2009 Jul;7(7):763-78. doi: 10.1586/erc.09.59. Review.

PMID:
19589113
27.

Will we be able to predict in which atrial fibrillation patients a rhythm control strategy will be successful?

Smit MD, Van Gelder IC.

Europace. 2009 Jul;11(7):846-7. doi: 10.1093/europace/eup148. No abstract available.

PMID:
19546186
28.

Should aldosterone blockade be used beyond current indications in heart failure?

Smit MD, van Gelder IC, Böhm M, Neuberger HR, van Veldhuisen DJ.

Curr Heart Fail Rep. 2009 Jun;6(2):117-25. Review.

PMID:
19486596
29.

The value and limitations of a wound inspection clinic after cardiac device implantation.

Deuling JH, Smit MD, Maass AH, Van den Heuvel AF, Nieuwland W, Zijlstra F, Van Gelder IC.

Eur J Cardiovasc Nurs. 2009 Oct;8(4):288-92. doi: 10.1016/j.ejcnurse.2009.02.007. Epub 2009 Mar 19.

PMID:
19299201
30.

Is inflammation a risk factor for recurrent atrial fibrillation?

Smit MD, Van Gelder IC.

Europace. 2009 Feb;11(2):138-9. doi: 10.1093/europace/eun338. Epub 2008 Dec 10. No abstract available.

PMID:
19074133
31.

New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'.

Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC.

Europace. 2008 Jun;10(6):668-73. doi: 10.1093/europace/eun124. Epub 2008 May 13. Review.

PMID:
18480076
32.

Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator.

Rienstra M, Smit MD, Nieuwland W, Tan ES, Wiesfeld AC, Anthonio RL, Van den Berg MP, Van Veldhuisen DJ, Van Gelder IC.

Am Heart J. 2007 Jan;153(1):120-6.

PMID:
17174649
33.

Right ventricular pacing and the risk of heart failure in implantable cardioverter-defibrillator patients.

Smit MD, Van Dessel PF, Nieuwland W, Wiesfeld AC, Tan ES, Anthonio RL, Van Erven L, Van Veldhuisen DJ, Van Gelder IC.

Heart Rhythm. 2006 Dec;3(12):1397-403. Epub 2006 Aug 10.

PMID:
17161779
34.

[Non-pharmacological treatment of heart failure: implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy].

van Gelder IC, Smit MD, Nieuwland W, van Veldhuisen DJ.

Ned Tijdschr Geneeskd. 2006 Oct 14;150(41):2238-44. Review. Dutch.

PMID:
17076357
35.

Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients.

Smit MD, Van Dessel PF, Rienstra M, Nieuwland W, Wiesfeld AC, Tan ES, Anthonio RL, Van Veldhuisen DJ, Van Gelder IC.

Europace. 2006 Aug;8(8):566-72.

PMID:
16864611
36.

Congener-specific model for polychlorinated biphenyl effects on otter (Lutra lutra) and associated sediment quality criteria.

Traas TP, Luttik R, Klepper O, Beurskens JE, Smit MD, Leonards PE, van Hattum AG, Aldenberg T.

Environ Toxicol Chem. 2001 Jan;20(1):205-12.

PMID:
11351410
37.

Polychlorinated biphenyls in the Eurasian otter (Lutra lutra).

Smit MD, Leonards PE, de Jongh AW, van Hattum BG.

Rev Environ Contam Toxicol. 1998;157:95-130. Review.

PMID:
9666742

Supplemental Content

Support Center